Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

China NT Pharma Group Co Ltd gives FY 2013 earnings guidance


Friday, 17 Jan 2014 06:19am EST 

China NT Pharma Group Co Ltd:Says based on a preliminary review of the group’s unaudited management accounts and the information currently available, the board currently estimates that the group will likely record a loss for FY 2013.The loss is mainly attributed to the group’s business restructuring measures introduced in 2012 which involved the exiting from its vaccine and pharmaceutical supply chain business.The downsizing of its vaccine sales and promotion team as well as the termination of its over-the-counter promotion business and several dermatological products.As a result, the group may incur further impairment charges for account receivables and inventories in relation to the terminated businesses, which will likely lead to a loss for FY 2013. 

Company Quote

0.93
0.0 +0.00%
17 Apr 2014